BTG (LON:BTG)‘s stock had its “neutral” rating reiterated by equities researchers at J P Morgan Chase & Co in a research note issued on Wednesday, November 15th.
Several other analysts also recently weighed in on the stock. Deutsche Bank reaffirmed a “buy” rating and set a GBX 775 ($10.38) price target on shares of BTG in a research note on Friday, October 6th. Numis Securities reaffirmed a “buy” rating and set a GBX 900 ($12.05) price target on shares of BTG in a research note on Wednesday, October 18th. Peel Hunt reaffirmed a “hold” rating and set a GBX 680 ($9.11) price target on shares of BTG in a research note on Tuesday, November 14th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 800 ($10.71) price target on shares of BTG in a research note on Wednesday, August 30th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of GBX 771.63 ($10.33).
Shares of BTG (BTG) opened at GBX 721.05 ($9.66) on Wednesday. BTG has a 12 month low of GBX 528.36 ($7.08) and a 12 month high of GBX 779 ($10.43).
BTG (LON:BTG) last announced its quarterly earnings data on Tuesday, November 14th. The company reported GBX 21 ($0.28) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of GBX 21 ($0.28). BTG had a net margin of 15.50% and a return on equity of 10.80%. The business had revenue of £341.30 million during the quarter.
TRADEMARK VIOLATION NOTICE: “BTG (BTG) Rating Reiterated by J P Morgan Chase & Co” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://ledgergazette.com/2017/12/02/btg-plc-btg-receives-neutral-rating-from-j-p-morgan-chase-co.html.
BTG Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.